



Patent Application
Attorney Docket No. PC9927C

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents P. O. Box 1450, Alexandria, VA 22313-1450 on this 13th day of August 20 3

By _____

Irene Graham

(Signature of person mailing)

Irene Graham

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Philip Albert Carpino, et al. :

APPLICATION NO.: 10/626,198 : Examiner: To Be Assigned

FILING DATE: July 22, 2003 : Group Art Unit: To Be Assigned

TITLE: Treatment of Insulin Resistance with Growth Hormone Secretagogues : _____

Hon. Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.


It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.



Patent Application
Attorney Docket No. PC9927C

Respectfully submitted,


A handwritten signature in black ink, appearing to read "John A. Wichtowski".

John A. Wichtowski
Attorney for Applicant(s)
Reg. No. 48,032

Date: 13 August 2003
Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-6645



INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>								ATTY. DOCKET NO. PC9927C			SERIAL NO. 10/626,198					
								APPLICANT Philip Albert Carpino, et al.								
								FILING DATE July 22, 2003						GROUP To Be Assigned		
U.S. PATENT DOCUMENTS																
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
	US	3	2	0	2	6	6	0	8/24/65	Zeile, et al.	260	254				
	US	3	2	3	5	5	5	0	2/15/66	Behner, et al.	260	243				
	US	4	4	1	1	8	9	0	10/25/83	Momany	424	177				
	US	4	5	4	4	6	6	4	10/1/85	Karjalainen, et al.	514	396				
	US	5	4	9	2	9	1	6	2/20/96	Morriello, et al.	514	318				
	US	6	1	0	7	3	0	6	8/22/00	Carpino, et al.	514	303				
	US	6	1	1	0	9	3	2	8/29/00	Carpino, et al.	514	3030				
	US	6	1	2	4	2	6	4	9/26/00	Carpino, et al.	514	19				
	US	6	1	2	7	3	9	1	10/3/00	Hansen, et al.	514	343				
	US	6	2	4	8	7	1	7	6/19/01	Carpino, et al.	514	19				
	US	6	4	4	8	2	6	3	9/10/02	Carpino, et al.	514	303				
FOREIGN PATENT DOCUMENTS																
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION			
													YES	NO		
	WO	9	3	0	3	4	1	9	2/18/93	International	G03C	7/305				
	WO	9	4	1	1	0	1	2	5/26/94	International	A61K	37/00				
	WO	9	4	1	3	6	9	6	6/23/94	International	C07K	5/02				
	WO	9	5	1	3	0	6	9	5/18/95	International	A61K	31/445				
	WO	9	7	0	8	1	6	6	3/6/97	International	C07D	401/12				
	WO	9	7	0	9	0	6	0	3/13/97	International	A61K	38/27				
	WO	9	7	2	3	5	0	8	7/3/97	International	C07K	14/60				
	WO	9	7	2	4	3	6	9	7/10/97	International	C07K	5/06				
	WO	9	8	5	8	9	4	7	12/30/98	International	C07K	5/023				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)																
			Aloi, et al., "Neuroendocrine Responses to a Novel Growth Hormone Secretagogue, L-692,429, in Healthy Older Subjects", <u>Journal of Endocrinology and Metabolism</u> 79(4), pp 943-949 (1994)													
			Aloia, et al., "Effects of Growth Hormone in Osteoporosis", <u>Journal of Clin. Endocrinol. Metab.</u> 43, pp. 992-999 (1976)													
			Arce, et al., "Synergistic Effect of Growth Hormone-Releasing Hormone (GHRH) and clonidine in Stimulating GH Release in Young and Old Dogs", <u>Brain Research</u> 537, pp. 359-362 (1990)													



INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>			ATTY. DOCKET NO. PC9927C	SERIAL NO. 10/626,198
			APPLICANT Philip Albert Carpino, et al.	
			FILING DATE July 22, 2003	GROUP To Be Assigned
		Arvat, et al., "Synergistic Effect of Growth Hormone-Releasing Hormone Restore the Blunted Growth Hormone-Releasing Acitivity of Hexarelin in Elderly Subjects", <u>Journal of Clinical Endocrinology and Metabolism</u> 79(5), pp. 1140-1143 (1994)		
		Binnerts, et al., "The Effects of Human Growth Hormone Administration in elderly Adults with Recent Weight Loss", <u>Journal of Clinical Endocrinology and Metabolism</u> 67(6), pp. 1312-1316 (1988)		
		Cella, et al., "Combined Administration of Growth-Hormone Releasing Hormone and Clonidine Restores Defective Growth Hormone Secretion in Old Dogs", <u>Neuroendocrinology</u> 57, pp. 432-438 (1993)		
		Cella, et al., "Presynaptic a2-Adrenergic Stimulation Leads to Growth Hormone Release in the Dog", <u>Life Sciences</u> 34, pp. 447-454 (1984)		
		Feek, et al., "The Effect of Bromocriptine on Insulin Secretion and Glucose Tolerance in Patients with Acromegaly", <u>Clinical Endocrinology</u> 15, pp. 473-478 (1981)		
		Gertz, et al., "L-692,429, a Nonpeptide Growth Hormone (GH) Secretagogue, Reverses Glucocorticoid Suppression of GH Secretion", <u>Journal of Clinical Endocrinology and Metabolism</u> 79(3), pp. 745-749 (1994)		
		Hampshire, et al., "Clonidine or Xylazine as Provocative Tests fro Growth Hormone Secretion in the Dog", <u>Am. Journal of Vet. Research</u> 42(6), pp. 1073-1076 (1981)		
		Hansen, et al., "Insulin Resistance in Acromegaly: Defects in Both Hepatic and Extrahepatic Insulin Action" <u>Am. Journ. Physiol.</u> 250, pp. E269-E273 (1986)		
		Jacks, et al., "Effect of Acute and Repeated Intravenous Administration of I-692,585, a Novel Non-Peptidyl Growth Hormone Secreagogue, on Plasma Growth Hormone, IGF-1, ACTH, Cortisol, Prolactin, Insulin, and Thyroxine Levels in Beagles", <u>Journal of Endocrinology</u> 143, pp. 399-406 (1994)		
		Jorgensen, et al., "Beneficial Effects of Growth Hormone Treatment in GH-Deficient Adults", <u>The Lancet</u> , pp. 1221-1224 (1989)		
		Levin, et al., "Cryohypophysectomy for Acromegaly", <u>The American Journal of Medicine</u> 57, pp. 526-535 (1974)		
		Maccario, et al., "Metabolic Modulation of the Growth Hormone-Releasing Activity of Hexarelin in Man", <u>Metabolism</u> 44(1), pp. 134-138 (1995)		
		Marcus, et al., "Effects of Short Term Administration of Recombinant Human Growth Hormone to Elderly People", <u>Journal of Clinical Endocrinology and Metabolism</u> 70(2), pp. 519-527 (1990)		
		Morrison, et al., "Orally Administered Clonidine as a Secretagogue of Growth Hormone and as Thymotropic Agent in Dogs of Various Ages", <u>Am. J. Vet. Res.</u> 51(1), pp. 65-70 (1990)		
		Rudman, et al., "Effects of Human Growth Hormone on Body Composition in Elderly Men", <u>Horm. Res.</u> 36(1), pp. 73-81 (1991)		
		Richelsen, et al., "Growth Hormone Treatment of Obese Women for 5 wk: Effect on Body Composition and Adipose Tissue LPL Activity", <u>Am. Journ. Physiol.</u> 266, pp. E211-E216, (1994)		
		Thorner, et al., "Growth Hormone-Releasing Hormone and Growth Hormone-Releasing Peptide as Therapeutic Agents to Enhance Growth Hormone Secretion in Disease and Aging", <u>Recent Progress in Hormone Research</u> 52, pp. 215-246 (1997)		
		Thorner, et al., Abstract 76084 of "Growth Hormone-Releasing Hormone and Growth Hormone-Releasing Peptide as Therapeutic Agents to Enhance Growth Hormone Secretion in Disease and Aging"		
		Valcavi, et al., "Alpha-2-Adrenergic Pathways Release Growth Hormone Via a Non-GRF-Dependent Mechanism in Normal Human Subjects", <u>Clinical Endocrinology</u> 29, pp. 309-316 (1988)		
EXAMINER			DATE CONSIDERED	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				